Pharmacokinetics of Prostate Cancer Lesions on Dual Time-Point PET/CT: A Predictive Factor for Response to PSMA Radioligand Therapy?

Authors:

Abstract
Prostate cancer (PC) lesions usually show increasing uptake of prostate-specific membrane antigen (PSMA) ligands over time. We investigated whether the intensity changes of PSMA-ligand uptake on dual-time-point positron emission tomography/computed tomography (PET/CT) can predict the response to [177Lu]Lu-PSMA radioligand therapy (PSMA-RLT). Nineteen patients who underwent dual-time-point [18F]PSMA-1007 PET/CT before PSMA-RLT were retrospectively analysed. Standardised uptake values were measured for local prostate cancer lesions and lymph node, bone, and organ metastases. These groups were compared for maximum standardised uptake value (SUVmax) differences between standard and late scans. Using Firth’s bias-reduced logistic regression, we assessed whether change in SUVmax between standard and late scans (ΔSUVmax) correlates with long-term biochemical response to PSMA-RLT. We analysed 355 PC lesions (14 local tumours, 171 bone, 132 lymph node, and 38 organ metastases). Across all lesions, the median SUVmax in late scans was 15.2% higher than that in standard scans (p<0.001). A mixed-effects model accounting for clustering within patients suggested differences in relative ΔSUVmax across metastasis types, although these did not reach statistical significance (p=0.058). Logistic regression showed no correlation of ΔSUVmax to therapy response likelihood (odds ratio=1.01, p=0.85). In contrast, the SUVmax of the hottest measured lesion significantly predicted the therapy response (odds ratio=1.11 per unit increase, 95% confidence interval: 1.02–1.26, p=0.005). PC lesions exhibited significantly higher PSMA-ligand uptake in late scans. However, the magnitude of this increase neither differed significantly across PC lesion types nor correlated with response to PSMA-RLT. Notably, higher SUVmax during standard time-point imaging were associated with an increased likelihood of biochemical response to PSMA-RLT.

This publication has 40 references indexed in Scilit: